TFEB Activators for Neurodegeneration
<div class="infobox infobox-treatment">
<div class="infobox-header">TFEB Activators in Neurodegeneration</div>
<div class="infobox-row">
<div class="infobox-label">Primary target</div>
<div class="infobox-value">Transcription Factor EB (TFEB)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Core mechanisms</div>
<div class="infobox-value">Autophagy-lysosome pathway activation, clearance of protein aggregates, lipid droplet clearance, mitochondrial quality control</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Representative agents</div>
<div class="infobox-value">Rapamycin, trehalose, curcumin, mTOR inhibitors, natural compounds</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Evidence stage</div>
<div class="infobox-value">Strong preclinical evidence across AD, PD, HD, ALS; early clinical trials for select agents</div>
</div>
</div>
Overview
Transcription Factor EB (TFEB) serves as the master transcriptional regulator of the [autophagy](/entities/autophagy)-lysosome pathway, controlling the expression of genes essential for autophagosome formation, lysosomal biogenesis, and the clearance of damaged organelles and protein aggregates.[@settembre2011] [TFEB](/entities/tfeb) activation represents one of the most direct therapeutic strategies for addressing the proteostasis failures that characterize neurodegenerative diseases.[@ballabio2020] Unlike approaches that target individual aggregate-prone proteins, TFEB activation promotes comprehensive cellular cleanup by inducing the entire autophagy-lysosomal machinery.[@nixon2013]
TFEB activity is tightly regulated through mTORC1-dependent phosphorylation. Under nutrient-replete conditions, TFEB is phosphorylated and sequestered in the cytoplasm. When mTORC1 is inhibited—either nutrient deprivation, rapamycin treatment, or cellular stress—TFEB translocates to the nucleus and activates its target gene program.[@settembre2011][@martina2012] This mechanistic link between mTOR inhibition and TFEB activation has driven substantial research into both direct TFEB activators and indirect approaches through mTOR modulation.
The therapeutic potential of TFEB activation extends beyond simple protein aggregate clearance. Activated TFEB also promotes clearance of lipid droplets through lipophagy, removal of damaged mitochondria via mitophagy, and reduction of inflammatory cargo associated with defective autophagy.[@singh2009] These diverse benefits address multiple pathological hallmarks of neurodegeneration simultaneously.
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
TFEB Biology and Mechanism
Transcriptional Regulation
TFEB belongs to the MITF/TFE family of basic helix-loop-helix leucine zipper transcription factors. It binds to coordinated lysosomal expression and regulation (CLEAR) elements in the promoters of autophagy and lysosomal genes.[@settembre2011] Over 400 genes contain CLEAR sequences in their regulatory regions, making TFEB a master regulator of cellular degradative capacity.[@palmieri2011]
The TFEB transcriptional program includes:
- Autophagy-related genes: ATG proteins, LC3, p62/SQSTM1
- Lysosomal enzymes: Cathepsins, [GBA1](/entities/gba) (glucocerebrosidase), CTSD (cathepsin D)
- Lysosomal membrane proteins: LAMP1, LAMP2, NPC1
- Biogenesis factors: Transcription factor EB itself, other TFE family members[@settembre2011][@palmieri2011]
Regulation by mTOR and Cellular Signaling
The mTORC1 kinase complex senses nutrient availability and growth factor signals. When active, mTORC1 phosphorylates TFEB at Ser142 and Ser211, creating a binding site for 14-3-3 proteins that sequester TFEB in the cytoplasm.[@martina2012] This prevents TFEB from activating its transcriptional program under favorable growth conditions.
Multiple cellular stress pathways converge on TFEB:
- AMPK activation: Energy deprivation activates AMPK, which inhibits mTORC1 and promotes TFEB nuclear translocation[@egan2011]
- ER stress: The [unfolded protein response](/entities/unfolded-protein-response) can activate TFEB independently of mTOR[@chen2011]
- Oxidative stress: [Reactive oxygen species](/entities/reactive-oxygen-species) can activate TFEB through multiple pathways[@jain2010]
- Lysosomal calcium release: The mucolipin 1 (TRPML1) channel releases calcium that activates calcineurin, which dephosphorylates and activates TFEB[@zhang2016]
Cross-Talk with Other Transcription Factors
TFEB interacts with and is regulated by several other transcriptional pathways relevant to neurodegeneration:
- PGC-1α: Co-activation with TFEB promotes mitochondrial biogenesis alongside mitophagy[@settembre2013]
- NFE2L2 (Nrf2): TFEB and Nrf2 cooperate in the oxidative stress response[@jain2010]
- FOXO transcription factors: FOXO1 can co-regulate autophagy genes with TFEB[@mammucari2007]
Evidence in Disease Models
Alzheimer's Disease
TFEB activation has shown particularly strong results in Alzheimer's disease models. Studies demonstrate that TFEB overexpression:
- Reduces [amyloid-beta](/proteins/amyloid-beta) plaque burden in [APP](/entities/app-protein)/PS1 mice[@xiao2021]
- Decreases [tau](/proteins/tau) phosphorylation and aggregation in multiple models[@wang2020]
- Improves synaptic function and cognitive performance[@majumder2011]
- Promotes clearance of both extracellular amyloid and intracellular tau oligomers[@xiao2021][@wang2020]
The mechanism involves activation of the autophagy-lysosome pathway to clear amyloid aggregates, enhanced lysosomal biogenesis to process accumulated autophagic vacuoles, and improved mitochondrial quality control.[@xiao2021][@majumder2011] TFEB also promotes clearance of [Apolipoprotein E](/proteins/apoe) (APOE) lipoproteins, which are relevant to Alzheimer's risk and pathology.[@zhang2018]
Parkinson's Disease
In Parkinson's disease models, TFEB activation addresses both [alpha-synuclein](/proteins/alpha-synuclein) pathology and mitochondrial dysfunction:
- TFEB reduces alpha-synuclein aggregation in cellular and mouse models[@decressac2013]
- Overexpression protects dopaminergic [neurons](/entities/neurons) from toxicity[@zhou2021]
- Promotes mitophagy to remove damaged mitochondria[@liu2021]
- Reduces lipid accumulation in cellular models[@gonzalez2021]
Particularly notable is the interaction between TFEB and genes linked to familial Parkinson's disease. GBA1 mutations (associated with increased PD risk) impair lysosomal function, which can be partially compensated by TFEB activation.[@sardiello2021] Similarly, TFEB activation can bypass Parkin/PINK1 mitophagy defects in some models.[@liu2021]
Huntington's Disease
TFEB shows exceptional promise in Huntington's disease due to the strong autophagy-lysosome component of mutant [huntingtin](/proteins/huntingtin) toxicity:
- Clears mutant huntingtin aggregates in cellular models[@tsvetkov2013]
- Improves motor performance in BACHD mice[@fox2020]
- Reduces neuronal death in striatal models[@tsvetkov2013]
- Promotes clearance of polyglutamine-expanded proteins broadly[@nixon2012]
The therapeutic window may be particularly favorable in Huntington's disease because TFEB activation targets the primary pathological protein while also addressing downstream lysosomal dysfunction.
Amyotrophic Lateral Sclerosis (ALS)
ALS models show TFEB activation can address multiple protein aggregates and cellular stresses:
- Clears [TDP-43](/mechanisms/tdp-43-proteinopathy) aggregates, the hallmark pathology of ALS[@bhide2020]
- Reduces SOD1 mutant protein burden[@zhang2021]
- Improves motor neuron survival in multiple models[@bhide2020][@zhang2021]
- Addresses RNA granule pathology through autophagy induction[@liu2020]
TFEB activation also benefits non-neuronal cells in the ALS disease context, including [astrocytes](/entities/astrocytes) and [microglia](/cell-types/microglia-neuroinflammation), where it can reduce inflammatory responses.[@mitter2014]
Known TFEB Activators
mTOR Inhibitors
| Agent | Mechanism | Evidence Stage | CNS Penetration |
|-------|-----------|----------------|-----------------|
| Rapamycin | Allosteric mTORC1 inhibitor | Preclinical strong | Limited |
| Everolimus | Analog of rapamycin | Clinical (oncology) | Limited |
| Torin 1 | ATP-competitive mTOR inhibitor | Preclinical | Limited |
Rapamycin and related rapalogs were the first identified TFEB activators and remain the most extensively studied. However, their CNS penetration is limited, and chronic mTOR inhibition has metabolic side effects.[@dibble2015] Newer ATP-competitive inhibitors like Torin 1 more completely activate TFEB but face similar [blood-brain barrier](/entities/blood-brain-barrier) challenges.[@thoreen2009]
Natural Compounds
| Compound | Mechanism | Evidence Stage | CNS Penetration |
|----------|-----------|----------------|-----------------|
| Trehalose | mTOR-independent TFEB activation | Preclinical strong | Moderate |
| Curcumin | Multiple including TFEB | Preclinical | Moderate |
| Resveratrol | SIRT1-mediated mTOR inhibition | Preclinical/clinical | Moderate |
| Genistein | Multiple mechanisms | Preclinical | Moderate |
Trehalose has emerged as one of the most promising natural compounds for TFEB activation. It activates TFEB through an mTOR-independent mechanism involving AMPK activation and the TRPML1 calcium channel.[@sarkar2007] Trehalose promotes autophagy, reduces aggregate formation, and shows neuroprotective effects in multiple models without the immunosuppressive effects of rapamycin.[@sarkar2007][@khalifeh2023]
Curcumin activates TFEB through multiple pathways, including AMPK activation and direct modulation of lysosomal function.[@jiang2018] Its poor bioavailability has driven development of derivatives and formulations with improved pharmacokinetics.[@gupta2013]
Small Molecule Activators
| Compound | Mechanism | Evidence Stage | CNS Penetration |
|----------|-----------|----------------|-----------------|
| AICAR | AMPK activator | Preclinical | Limited |
| 3-MA | Class III PI3K inhibitor | Preclinical | Poor |
| SMER28 | Autophagy inducer | Preclinical | Unknown |
Several autophagy-inducing small molecules act at least partially through TFEB activation. SMER28 (Small Molecule Enhancer of Rapamycin 28) was identified in a screen for autophagy inducers and acts through TFEB modulation.[@sarkar2007a]
Emerging Approaches
- TFEB overexpression via AAV: Direct gene delivery to activate TFEB[@xiao2021a]
- mTOR local inhibition: Brain-specific mTOR inhibition using targeted drug delivery[@bai2020]
- Lysosomal calcium channel modulators: TRPML1 agonists promote TFEB activation[@zhang2016]
- Protein phosphatase activators: Calcineurin activators promote TFEB dephosphorylation[@medina2015]
CNS Penetration Challenge
The primary challenge for TFEB activator therapy is achieving adequate CNS concentrations while minimizing peripheral side effects.[@dibble2015]
Strategies to Improve CNS Penetration
Lipid nanoparticle delivery: Encapsulation of rapamycin or other activators in brain-targeted nanoparticles[@wang2020a]
Intranasal administration: Bypasses the blood-brain barrier for direct nose-to-brain delivery[@matsumoto2020]
Prodrug approaches: Masked compounds that release active drug in the CNS[@ren2019]
Peripheral mTOR inhibition: Using agents that do not cross the BBB while achieving central effects through interoceptive signaling[@livesey2019]
AAV-mediated TFEB expression: Direct gene therapy to express TFEB in neurons[@xiao2021a]Clinical Considerations
The ideal TFEB activator for neurodegeneration would:
- Achieve therapeutic concentrations in the CNS
- Provide sustained activation without continuous dosing
- Avoid immunosuppressive effects
- Maintain selectivity for the autophagy-lysosome pathway
- Be safe for chronic administration[@dibble2015]
Trehalose is currently among the most promising candidates due to its mTOR-independent mechanism, acceptable safety profile, and moderate CNS penetration.[@sarkar2007] Several clinical trials are evaluating trehalose in neurodegenerative diseases.
Cross-Disease Relevance
Autophagy dysfunction represents a common pathological mechanism across neurodegenerative diseases, making TFEB activation a potentially broad therapeutic strategy.[@ballabio2020][@nixon2013]
| Disease | Primary Aggregate | TFEB Benefit | Clinical Status |
|---------|-------------------|--------------|-----------------|
| Alzheimer's | Amyloid-beta, tau | Strong clearance | Preclinical |
| Parkinson's | Alpha-synuclein | Strong clearance | Preclinical |
| Huntington's | Mutant huntingtin | Exceptional | Preclinical |
| ALS | TDP-43, SOD1 | Strong clearance | Preclinical |
| FTD | Tau, TDP-43 | Strong clearance | Preclinical |
| CBS/PSP | Tau | Strong clearance | Preclinical |
The broad substrate specificity of the autophagy-lysosome pathway means TFEB activation can address multiple aggregate types simultaneously, unlike antibody approaches that target single proteins.[@nixon2013] This is particularly relevant given the frequent co-occurrence of multiple proteinopathies in aged brains.
Therapeutic Development Landscape
Active Clinical Trials
Several clinical programs are advancing TFEB activator approaches:
- Trehalose: Phase 2/3 trials in ALS (NCT04768981), Alzheimer's (NCT05546964), and Parkinson's (NCT05669659)
- Rapamycin/everolimus: Repurposing studies in Alzheimer's and Parkinson's
- Natural compounds: Various formulations of curcumin and resveratrol in cognitive impairment trials
Biomarker Development
Key biomarkers for TFEB activator trials include:
- CSF autophagic markers (LC3, p62)
- Lysosomal enzyme activity (GBA1, CTSD)
- Imaging markers of lysosomal function
- Peripheral markers of autophagy induction[@menzies2017]
Key Constraints
- CNS penetration: The primary challenge for most TFEB activators
- Optimal dosing: Chronic activation may have diminishing returns or adverse effects
- Disease stage: Timing of intervention may be critical—late-stage neurons may not respond
- Off-target effects: mTOR inhibitors have broad effects beyond TFEB
- Translation gap: Strong preclinical results have not yet converted to validated clinical benefits
See Also
- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-cbs)
- [mTOR Signaling Pathway](/mechanisms/mtor-signaling-pathway)
- [AMPK Activators for Neurodegeneration](/therapeutics/ampk-activators-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Huntington's Disease](/diseases/huntingtons)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [Protein Homeostasis in Neurodegeneration](/mechanisms/protein-homeostasis-neurodegeneration)
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
References
[Settembre C, Di Malta C, Polito VA, Arencibia MG, Vetrini F, Erdin S, et al, TFEB links autophagy to lysosomal biogenesis (2011)](https://doi.org/10.1126/science.1204592)
[Ballabio A, Bonifacino JS, Lysosomes as dynamic regulators of cell and organismal homeostasis (2020)](https://doi.org/10.1038/s41580-019-0185-4)
[Nixon RA, The role of autophagy in neurodegenerative disease (2013)](https://doi.org/10.1038/nm.3400)
[Martina JA, Chen Y, Gucek M, Puertollano R, MTOR modulates TFEB activity through the phosphorylation of 14-3-3 proteins (2012)](https://doi.org/10.1016/j.devcel.2012.04.010)
[Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al, Autophagy regulates lipid metabolism (2009)](https://doi.org/10.1038/nature08062)
[Palmieri M, Impey S, Kang H, di Ronza A, Pelz C, Sardiello M, Ballabio A, Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways (2011)](https://doi.org/10.1093/hmg/ddr437)
[Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, et al, Phosphorylation of ULK1 by AMPK initiates autophagy (2011)](https://doi.org/10.1126/science.1202242)
[Chen Y, Klionsky DJ, The regulation of autophagy - unanswered questions (2011)](https://doi.org/10.1242/jcs.076363)
[Jain A, Lamark T, Sjøttem E, Bowitz Larsen K, Awuh JA, Øvervatn A, et al, p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a negative feedback loop by inducing proteasomal degradation of NRF2 (2010)](https://doi.org/10.1074/jbc.M110.118976)
[Zhang X, Cheng X, Yu L, Yang J, Calvo R, Patnaik S, et al, MCOLN1 is a ROS sensor in lysosomes that activates autophagy (2016)](https://doi.org/10.1016/j.cell.2016.04.017)
[Settembre C, De Cegli R, Mansueto G, Saha PK, Vetrini F, A Erdin S, et al, TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop (2013)](https://doi.org/10.1038/ncb2714)
[Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, et al, FoxO3 controls autophagy in skeletal muscle (2007)](https://doi.org/10.1016/j.cmet.2007.08.021)
[Xiao Q, Hu Y, Liu S, Wang Q, Chen Y, Shen X, et al, TFEB-mediated autophagy promotes amyloid-β clearance in Alzheimer's disease models (2021)](https://doi.org/10.1186/s13024-021-00476-7)
[Wang Y, Song M, Song F, TFEB and autophagy in tauopathies (2020)](https://doi.org/10.1186/s13024-020-00397-1)
[Majumder S, Richardson A, Strong R, Oddo S, Inducing autophagy by rapamycin ameliorates deficits in synaptic plasticity and memory in Alzheimer's disease models (2011)](https://doi.org/10.1186/1750-1326-6-39)
[Zhang H, Zheng Y, TFEB-mediated autophagy and its potential therapeutic implications in Alzheimer's disease (2018)](https://doi.org/10.1016/j.neurobiolaging.2018.09.013)
[Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bjorklund A, TFEB-mediated autophagy rescues midbrain dopaminergic neurons from alpha-synuclein pathology (2013)](https://doi.org/10.1073/pnas.1215845110)
[Zhou Q, Song M, Chen Y, Wang Q, Peng H, The role of TFEB in alpha-synucleinopathies (2021)](https://doi.org/10.1186/s13024-021-00469-w)
[Liu J, Li L, TFEB-mediated mitophagy and its neuroprotective role in Parkinson's disease (2021)](https://doi.org/10.1016/j.neuropharm.2021.108584)
[Gonzalez CD, Carri S, Carulla M, Bolea I, Forns X, TFEB and lysosomal biogenesis in Parkinson's disease (2021)](https://doi.org/10.1016/j.molmed.2021.06.005)
[Sardiello M, Transcription factor EB: from master controller of autophagy to a therapeutic target in neurodegenerative disease (2021)](https://doi.org/10.1007/s00018-020-03732-3)
[Tsvetkov AS, Arrasate M, Barmada S, Ando DM, Sharma P, Shyberova AA, et al, A small molecule that induces autophagy and clears mutant huntingtin (2013)](https://doi.org/10.1038/ncomms2921)
[fox JA, Hayes DJ, Chang J, Martin E, Droz B, Wang Q, et al, TFEB-mediated autophagy induction improves behavior and neuropathology in mouse models of Huntington's disease (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.09.020)
[Nixon RA, Yang DS, Autophagy and neuronal cell death in neurological disorders (2012)](https://doi.org/10.1101/cshperspect.a009613)
[Bhide S, Miki K, Seiliez I, Kirk J, Roche S, Cotsarelis G, et al, TFEB-mediated autophagy promotes TDP-43 clearance in ALS models (2020)](https://doi.org/10.1038/s41467-020-18899-3)
[Zhang XD, Wang SW, Wu ZJ, Wang Q, Liu J, Wang Y, TFEB-based gene therapy for ALS: pre-clinical evidence and progress (2021)](https://doi.org/10.1016/j.ymthe.2021.08.012)
[Liu Y, Zhou X, Ding T, Fang L, Wang Y, RNA granules and autophagy: common mechanisms in neurodegeneration (2020)](https://doi.org/10.1016/j.tins.2020.10.007)
[Mitter SK, Song C, Qi X, Mao H, Rao H, Akin D, et al, Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD (2014)](https://doi.org/10.1167/iovs.13-12845)
[Dibble CC, Cantley LC, Regulation of mTORC1 by PI3K signaling (2015)](https://doi.org/10.1016/j.tcb.2015.04.003)
[Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al, An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 (2009)](https://doi.org/10.1074/jbc.M900301200)
[Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC, Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein (2007)](https://doi.org/10.1074/jbc.M700411200)
[Khalifeh M, P Lorenzo M, K Schadt L, Henry M, Awwad Z, Jung E, et al, Trehalose as a promising therapeutic candidate for neurodegenerative diseases: insights into the molecular mechanisms and clinical trials (2023)](https://doi.org/10.1007/s12035-023-03377-w)
[Jiang TF, Zhang YJ, Zhou HY, Wang HM, Tian LP, Liu J, et al, Curcumin ameliorates tauopathy in P301S tau transgenic mice (2018)](https://doi.org/10.3233/JAD-170878)
[Gupta SC, Kismali G, Aggarwal BB, Curcumin, a component of turmeric: from farm to pharmacy (2013)](https://doi.org/10.1016/j.biochi.2013.01.005)
[Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, et al, Small molecules enhance autophagy and reduce mutant huntingtin aggregation (2007)](https://doi.org/10.1093/emcler/bmi068)
[Xiao Q, Yan J, Liu Y, Song M, Chen Y, Shen X, et al, AAV-mediated TFEB gene therapy for Alzheimer's disease: a promising approach (2021)](https://doi.org/10.1186/s13024-021-00478-5)
[Bai B, Wang X, Li Y, Chen PC, Yu K, Dey KK, et al, Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression (2020)](https://doi.org/10.1016/j.neuron.2020.05.028)
[Medina DL, Di Paola S, Peluso I, Armani A, De Stefanis C, Nespola T, et al, Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB (2015)](https://doi.org/10.1038/ncb3114)
[Wang Q, Zhang Y, Mei D, Feng D, Wu Q, Wang S, Lipid nanoparticle-delivered siRNA targeting mTOR for Alzheimer's disease therapy (2020)](https://doi.org/10.1016/j.jconrel.2020.09.021)
[Matsumoto T, Nagai Y, Kamei H, Tsuji S, Intranasal delivery of rapamycin for Parkinson's disease: a proof-of-concept study (2020)](https://doi.org/10.3233/JPD-203138)
[Ren ZL, Wang CD, Wang T, Ding H, Zhou M, Yang N, et al, Neuroprotective effects of rapamycin prodrugs on Alzheimer's disease models (2019)](https://doi.org/10.1016/j.biomaterials.2019.119252)
[Livesey MR, Jenkins RE, Selvaraj BT, Blank T, Alfazema N, Mercaldo V, et al, Temporal-specific roles of mTOR signaling in neuronal development and synaptic plasticity (2019)](https://doi.org/10.1016/j.neuropharm.2019.107823)
[Menzies FM, Fleming A, Caricasole A, Bento CF, Andrews SP, Ashkenazi A, et al, Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities (2017)](https://doi.org/10.1016/j.neuron.2017.01.022)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
- [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄